Cure8 research brief
Researchers tested a ginger-derived glucan that reduced inflammation and reshaped the gut microbiota in a mouse colitis model — a potential prebiotic approach that could inform future IBD therapies or dietary strategies.
Researchers in microbiome and prebiotic research; clinicians following preclinical IBD therapeutics; patients interested in microbiome-focused dietary approaches.
This paper reports the isolation and structural characterization of a glucan (ZOP-1a) from Zingiber officinale (ginger) and tests its effects in a mouse model of dextran-sodium-sulfate (DSS)–induced colitis.
The authors found that ZOP-1a reduced colon injury measures in mice, inhibited NF-κB/MAPK signaling, altered gut microbiota composition to increase short-chain fatty acid–producing bacteria, and that fecal microbiota transplant from treated mice transferred some benefit to recipients.
The work is preclinical and based on mouse experiments plus in vitro fermentation and microbiota-transfer experiments; it does not provide human data. The authors present structural chemistry of the polysaccharide and multiple mechanistic readouts in animals and microbiota assays.
If you have IBD, this is an early-stage laboratory study suggesting a ginger-derived polysaccharide might affect gut bacteria and inflammation in mice; it does not mean the compound is safe or effective in people, and it should not be used as medical treatment.
Results are from preclinical mouse and in vitro experiments reported in the journal abstract; they are not clinical trial data and do not establish safety or efficacy in humans.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: Natural Science Foundation of Hubei Province, award 2026AFC0837; National Natural Science Foundation of China, award 32260129; National Natural Science Foundation of China, award 82304892
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study identifies a fungal β-glucan that reduced inflammation and altered the gut microbiome and short-chain fatty acids in a mouse model of ulcerative colitis, which could inform future nutritional or therapeutic...
The study identifies a plant-derived compound that reduced inflammation and liver injury in a mouse model of ulcerative colitis and ties its effects to both JAK2/STAT1 inhibition and changes in the gut microbiota—two...
The study identifies a specific gut microbe and a bile-acid metabolite that reduced inflammation in a mouse colitis model and implicates STAT3/NF-κB pathways — a potential new avenue for microbiome-based therapeutics for...
